3 Key Takeaways
Plain English Summary- 01Core Finding
We examined the mechanisms determining these distinct outcomes in cancer.
- 02Study Evidence
Tested in a laboratory experimental model (preclinical discovery) at the preclinical stage.
- 03Practical Meaning
Consistently, PRKN expression negatively correlated with immune infiltration in human cancers.
What This Means for You
The balance between mtDNA and cytochrome c (cyt.c) release defined two immunologically distinct outcomes: immunogenic cell death (ICD) and apoptosis. In preclinical models, combined inhibition of MEK and mitophagy induced robust dendritic cell (DC) activation and promoted CD8 + T cell-mediated antitumor immunity. Consistently, PRKN expression negatively correlated with immune infiltration in human cancers. Collectively, these findings provide a rationale for combination strategies targeting mitochondrial dynamics to augment antitumor immunity.
The Discovery
Cells experiencing mitochondrial stress can undergo apoptosis or cell death that triggers innate immune activation. We examined the mechanisms determining these distinct outcomes in cancer. Abundant mitochondrial DNA (mtDNA) and high expression of the cGAS-STING pathway were features of KRAS-mutant cancers. In a pharmacological screen, MEK inhibitor (MEKi) effectively induced mtDNA release into the cytosol in KRAS-mutant cancer cells. However, MEKi also induced PRKN-mediated mitophagy, which limited mtDNA release by eliminating damaged mitochondria. Inhibition of mitophagy sustained mtDNA efflux and amplified cGAS-STING signaling. Mechanistically, PRKN-mediated mitophagy restrained mitochondrial outer membrane permeabilization (MOMP) to limit mtDNA efflux.
How It Works, Simply
This immunology research focuses on T cells · Immune response · Genetics. Researchers evaluated it using a laboratory experimental model (Preclinical discovery) at the preclinical stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
We examined the mechanisms determining these distinct outcomes in cancer.
- 02Study Evidence
Tested in a laboratory experimental model (preclinical discovery) at the preclinical stage.
- 03Practical Meaning
Consistently, PRKN expression negatively correlated with immune infiltration in human cancers.
Biological Mechanism & Study Design
Study Design & Cohort
Laboratory research
Laboratory experimental model (Preclinical discovery) · Preclinical
Biological Pathway & Modality
T cells · Immune response · Genetics
Intervention: Mitochondrial DNA abundance is a determinant of immunogenic cell death in cancer
Experimental Findings & Endpoints
Cells experiencing mitochondrial stress can undergo apoptosis or cell death that triggers innate immune activation.
We examined the mechanisms determining these distinct outcomes in cancer. Abundant mitochondrial DNA (mtDNA) and high expression of the cGAS-STING pathway were features of KRAS-mutant cancers.
In a pharmacological screen, MEK inhibitor (MEKi) effectively induced mtDNA release into the cytosol in KRAS-mutant cancer cells. However, MEKi also induced PRKN-mediated mitophagy, which limited mtDNA release by eliminating damaged mitochondria.
Inhibition of mitophagy sustained mtDNA efflux and amplified cGAS-STING signaling. Mechanistically, PRKN-mediated mitophagy restrained mitochondrial outer membrane permeabilization (MOMP) to limit mtDNA efflux.
Clinical Translation & Practice Context
The balance between mtDNA and cytochrome c (cyt.c) release defined two immunologically distinct outcomes: immunogenic cell death (ICD) and apoptosis.
In preclinical models, combined inhibition of MEK and mitophagy induced robust dendritic cell (DC) activation and promoted CD8 + T cell-mediated antitumor immunity. Consistently, PRKN expression negatively correlated with immune infiltration in human cancers.
Collectively, these findings provide a rationale for combination strategies targeting mitochondrial dynamics to augment antitumor immunity.
The Bottom Line · Clinical Pearl
“Collectively, these findings provide a rationale for combination strategies targeting mitochondrial dynamics to augment antitumor immunity.”
Published in Immunity · Current Stage: Preclinical
